印度制药部门在北美和国内销售的推动下实现了10%的强劲增长。 India's pharmaceutical sector sees robust 10% growth, fueled by North American and domestic sales.

印度制药部门在25财政年度第二季度的同比年增长率为10%,其驱动力是北美和国内的强劲表现。 India's pharmaceutical sector saw a 10% year-on-year growth in the second quarter of FY25, driven by strong performances in North America and domestically. 慢性疗法增加了9%,保健部门的最高收入逐年增长17.6%。 Chronic therapies increased by 9%, and the healthcare sector showed a 17.6% year-on-year rise in top-line revenue. 预计今后三年将出现积极的前景,在生物类、GLP-1和peptides等生物类、GLP-1和peptides方面出现了有希望的发展。 A positive outlook is projected for the coming three years, with promising developments in biosimilars, GLP-1, and peptides.